PKI dividend history

 Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world's greatest health challenges Trusted partner to pharma, government and diagnostics customers with complete, end-to-end solutions To begin trading as RVTY under new name on May 16th (NYSE:PKI) Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. Born from two words, "revolutionize" (rev) and "vita" (vit) meaning "life" in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure. The Company was prev

The Board of Directors of PerkinElmer, Inc. (NYSE:PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 11, 2023 to all shareholders of record at the close of business on July 21, 2023. About The PerkinElmer Life Sciences and Diagnostics Company The PerkinElmer Life Sciences and Diagnostics company – which is to be renamed during the second quarter of 2023 – provides end-to-end solutions that help scientists, researchers and clinicians better diagnose disease and discover new and more personalized drugs. The Company reported revenues of approximately $3.3 billion in 2022, serves customers in 190 countries, and is a compon

CALGARY, AB, March 13, 2023 /PRNewswire/ - Parkland Corporation ("Parkland") (TSX:PKI) announces that a dividend of $0.34 per share will be paid on April 14, 2023 to shareholders of record on March 22, 2023. The dividend will be an 'eligible dividend' for Canadian income tax purposes. The ex-dividend date is March 21, 2023. Forward-Looking Statements Certain statements contained in this news release constitute forward-looking information and statements (collectively, "forward looking statements"). When used in this news release, the words "expect'', ''will'', ''could'', ''woul

Transforms into new Life Sciences and Diagnostics company PerkinElmer Inc. (NYSE:PKI), today announced that it has successfully completed the previously announced divestiture of its Applied, Food and Enterprise Services businesses to New Mountain Capital, a growth-oriented investment firm. The resulting new, high-growth Life Sciences and Diagnostics business, focused on developing and delivering novel scientific breakthroughs that will have a profound impact on improving global health, will share the PerkinElmer name with the Applied, Food and Enterprise Services businesses until a new name, brand and ticker symbol is unveiled in Q2 2023 pending shareholder approval. "Today marks the cul

The Board of Directors of PerkinElmer, Inc. (NYSE:PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 12, 2023 to all shareholders of record at the close of business on April 21, 2023. About PerkinElmer PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $5 billion in 2021, has more than 16,000 employees serving customers in 190 countries, and is a component of the S&P 500 Index. Additional information is available at www.perkinelmer.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20230126005743/en/

The Board of Directors of PerkinElmer, Inc. (NYSE:PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 10, 2023 to all shareholders of record at the close of business on January 20, 2023. About PerkinElmer PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $5 billion in 2021, has more than 16,000 employees serving customers in 190 countries, and is a component of the S&P 500 Index. Additional information is available at www.perkinelmer.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20221026005219/en/

Enters agreement with intention to divest Applied, Food and Enterprise Services businesses PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced it has entered into an agreement with the intention to divest its Applied, Food and Enterprise Services businesses to New Mountain Capital, a leading growth-oriented private equity firm, for total consideration of $2.45 billion in cash, $2.30 billion of which will be received at the closing and $150 million of which will be payable contingent on the exit valuation New Mountain Capital receives on a sale or other capital events related to the business. "Today's announcement is a pivotal step i

The Board of Directors of PerkinElmer, Inc. (NYSE:PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 11, 2022 to all shareholders of record at the close of business on October 21, 2022. About PerkinElmer PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $5 billion in 2021, has more than 16,000 employees serving customers in 190 countries, and is a component of the S&P 500 Index. Additional information is available at www.perkinelmer.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20220722005023/en/

The Board of Directors of PerkinElmer, Inc. (NYSE:PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 12, 2022 to all shareholders of record at the close of business on July 22, 2022. About PerkinElmer PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $5 billion in 2021, has more than 16,000 employees serving customers in 190 countries, and is a component of the S&P 500 Index. Additional information is available at www.perkinelmer.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005199/en/

The Board of Directors of PerkinElmer, Inc. (NYSE:PKI), declared a regular quarterly dividend of $0.07 per share of common stock January 27, 2022. This dividend is payable on May 13, 2022 to all shareholders of record at the close of business on April 22, 2022. About PerkinElmer PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $3.8 billion in 2020, has more than 16,000 employees serving customers in 190 countries, and is a component of the S&P 500 Index. Additional information is available at www.perkinelmer.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005653/en/

New NGS workflow accelerates the detection of SARS-CoV-2 variants including Omicron PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the research use only (RUO) launch of the NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit v2 to accelerate the detection of SARS-CoV-2 variants. This complete next generation sequencing (NGS) solution will allow laboratories to increase sequencing throughput and make reliable variant identifications. Using positive SARS-CoV-2 samples, the NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 detects mutations associated with all SARS-CoV-2 variants, including the latest Variant of Concern (VOC) identified by the World Healt

Report highlights stewardship and sustainability progress and solidifies new ESG commitments PerkinElmer, Inc. (NYSE:PKI), a global leader innovating for a healthier world, today released its 2021 Corporate Social Responsibility (CSR) Report, which summarizes the latest achievements of its environmental, social and governance (ESG) program. The report titled, "Strengthening Our Commitments for Sustainable Impact," also outlines four new ESG commitments unveiled by the Company earlier this year and describes its reporting framework established in accordance with guidelines from The Sustainability Accounting Standards Board (SASB). PerkinElmer's 2021 CSR Report is organized by the three pil

The Board of Directors of PerkinElmer, Inc. (NYSE:PKI), declared a regular quarterly dividend of $0.07 per share of common stock October 27, 2021. This dividend is payable on February 11, 2022 to all shareholders of record at the close of business on January 21, 2022. About PerkinElmer PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $3.8 billion in 2020, has about 15,000 employees serving customers in 190 countries, and is a component of the S&P 500 Index. Additional information is available at www.perkinelmer.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005996/e

PerkinElmer, Inc. (NYSE:PKI) a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents for a total consideration of approximately $5.25 billion. The acquisition, the largest in PerkinElmer's history, further expands the Company's life science franchise into high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation and bioprocessing. Commenting on the collaboration ahead, Prahlad Singh, president and chief executive officer of PerkinElmer, said "BioLegend's stellar leaders, teams and technologi

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock July 23, 2021. This dividend is payable on November 12, 2021 to all shareholders of record at the close of business on October 22, 2021. About PerkinElmer PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $3.8 billion in 2020, has about 14,000 employees serving customers in 190 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

The Board of Directors of PerkinElmer, Inc. (NYSE:PKI), declared a regular quarterly dividend of $0.07 per share of common stock July 23, 2021. This dividend is payable on November 12, 2021 to all shareholders of record at the close of business on October 22, 2021. About PerkinElmer PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $3.8 billion in 2020, has about 14,000 employees serving customers in 190 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com. View source version on businesswire.com: https://www.businesswire.com/ne

Company anticipates 2Q21 revenue and earnings to be above previously communicated guidance PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced ahead of this morning's Virtual Investor and Analyst Day that it anticipates exceeding its previously announced financial guidance for the second quarter ending July 4, 2021, driven by broad-based momentum across both COVID and non-COVID businesses. Presentations from company executives for this morning's Investor and Analyst Day will begin at 8:30 a.m. ET and conclude at approximately to 11:30 a.m. ET. All participants are requested to register prior to the start of the event. The link can b

Solutions to complement Company's growing position in cell and gene therapy research and development PerkinElmer, Inc. (NYSE:PKI) ("PerkinElmer") is pleased to announce it has entered into an agreement to acquire SIRION Biotech GmbH, a leading, global provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies. The acquisition is expected to close during the third quarter of 2021. Headquartered in Munich, Germany, privately held SIRION has approximately 50 employees based in Germany, the U.S. and France. The company has established a strong licensing portfolio leveraged by over a dozen major pharmaceutical and biotech players researchin

Endocrinology testing specialist expands PerkinElmer's immunodiagnostics segment PerkinElmer, Inc. (NYSE:PKI) ("PerkinElmer") and Immunodiagnostic Systems Holdings PLC (LSE: IHS) ("IDS") are pleased to announce that they have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire IDS for approximately $155 million (£110 Million). The transaction has a total enterprise value of approximately $124 million (£88 Million) and is expected to close early in the third quarter of 2021, subject to approvals from the shareholders of IDS, sanction by the High Court of Justice in England and Wales and other customary closing conditions for a public takeover i

Highly complementary cell counting and analysis capabilities bolster preclinical portfolio and enhance QA/QC capabilities in cell and gene therapy and biologics manufacturing PerkinElmer, Inc. (NYSE:PKI) is pleased to announce it has entered into an agreement to acquire Nexcelom Bioscience for $260 Million in cash. The transaction is expected to close during the second quarter of 2021. Nexcelom is a leading, global provider of automated cell counting instruments, image cytometry workstations, assays and a variety of cell reagents, consumables, and fit-for-purpose cell counting method selection and development instructions that follow ISO Cell Counting Standards and aid in the development

The Board of Directors of PerkinElmer, Inc. (NYSE:PKI), declared a regular quarterly dividend of $0.07 per share of common stock April 29, 2021. This dividend is payable on August 6, 2021 to all shareholders of record at the close of business on July 16, 2021. About PerkinElmer PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $3.8 billion in 2020, has about 14,000 employees serving customers in 190 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com. View source version on businesswire.com: https://www.businesswire.com/news/ho

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). PerkinElmer originally announced its intent to acquire Oxford Immunotec on January 7, 2021. “Oxford Immunotec’s global role in fighting tuberculosis, particularly its trademark product, the T-SPOT®.TB test, and the operations it has built are remarkable,” said Prahlad Singh, PerkinElmer president and chief executive officer. “We recognize the distinct clinical and logistical advantages of the test and see a great opportuni

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today provided an update on the COVID-19 Valencia Branch Laboratory’s (VBL) accreditation process. The VBL is operated by PerkinElmer in partnership with the California Department of Public Health (CDPH). The VBL started operations on November 1, 2020, and Laboratory Field Services (LFS) performed its routine inspection on December 8, 2020. The VBL received LFS’s routine inspection report on February 19, 2021, and PerkinElmer’s response is due by March 1, 2021. During the months of December and January, the VBL supplied additional information at LFS’s req

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock January 28, 2021. This dividend is payable on May 7, 2021 to all shareholders of record at the close of business on April 16, 2021. About PerkinElmer PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $2.9 billion in 2019, has about 14,000 employees serving customers in 190 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.